Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders

被引：10
|
作者：
Tendas, Andrea [1 ,2 ]
Lissia, Maria Felicita [1 ,2 ]
Piccioni, Daniela [1 ,2 ]
Tirimbelli, Liliana [1 ,2 ]
Scaramucci, Laura [1 ,2 ]
Giovannini, Marco [1 ,2 ]
Dentamaro, Teresa [1 ,2 ]
Perrotti, Alessio [1 ,2 ]
de Fabritiis, Paolo [1 ,2 ]
Niscola, Pasquale [1 ,2 ,3 ]
机构：
[1] St Eugenio Hosp, Hematol Unit, I-00144 Rome, Italy
[2] St Eugenio Hosp, Dept Pharm Serv, I-00144 Rome, Italy
[3] St Eugenio Hosp, Div Hematol, I-00144 Rome, Italy
来源：
SUPPORTIVE CARE IN CANCER | 2015年 / 23卷 / 02期
关键词：
5-DAY;
D O I：
10.1007/s00520-014-2502-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：303 / 305
页数：3
相关论文
共 39 条
  • [1] Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders
    Andrea Tendas
    Maria Felicita Lissia
    Daniela Piccioni
    Liliana Tirimbelli
    Laura Scaramucci
    Marco Giovannini
    Teresa Dentamaro
    Alessio Perrotti
    Paolo de Fabritiis
    Pasquale Niscola
    Supportive Care in Cancer, 2015, 23 : 303 - 305
  • [2] Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome
    Komrokji, Rami S.
    Al Ali, Najla H.
    Alrawi, E.
    Padron, Eric
    Perkins, Janelle
    Field, Teresa
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 745 - 746
  • [3] Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome
    Kitamura, Hiroaki
    Miyahara, Koichi
    Kubota, Yasushi
    Tomimasu, Rika
    Kimura, Shinya
    Miyahara, Masaharu
    EJHAEM, 2021, 2 (03): : 653 - 654
  • [4] Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
    Makita, Shinichi
    Munakata, Wataru
    Watabe, Daisuke
    Maeshima, Akiko Miyagi
    Taniguchi, Hirokazu
    Toyoda, Kosuke
    Yamauchi, Nobuhiko
    Fukuhara, Suguru
    Maruyama, Dai
    Kobayashi, Yukio
    Tobinai, Kensei
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2017, 45 (02) : 886 - 893
  • [5] THERAPY-RELATED MYELODYSPLASTIC SYNDROME: AN ANALYSIS OF 5 RISK MODELS IN PATIENTS TREATED WITH AZACITIDINE
    Duong, V.
    Lancet, J.
    Al-Ali, N.
    List, A.
    Komrokji, R.
    HAEMATOLOGICA, 2012, 97 : 368 - 369
  • [6] Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule
    Voso, M. T.
    Fianchi, L.
    Criscuolo, M.
    Greco, M.
    D'Alo, F.
    Hohaus, S.
    Pagano, L.
    Leone, G.
    LEUKEMIA RESEARCH, 2012, 36 (01) : E15 - E17
  • [7] A Phase 1b Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders
    Sternberg, Alex
    Boucher, Rebecca H.
    Coulthard, Helen C.
    Raghavan, Manoj
    Culligan, Dominic J.
    Jackson, Aimee
    Cargo, Catherine
    Dennis, Mike
    Metzner, Marlen
    Moore, Rachel
    Bowen, David
    Vyas, Paresh
    BLOOD, 2020, 136
  • [8] Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)
    Sternberg, Alexander
    Boucher, Rebecca
    Coulthard, Helen Chantal
    Raghavan, Manoj
    Culligan, Dominic
    Jackson, Aimee
    Cargo, Catherine
    Dennis, Mike
    Metzner, Marlen
    O'Sullivan, Jennifer
    Moore, Rachel
    Bowen, David
    Vyas, Paresh
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 222 - 229
  • [9] Coombs' test positive autoimmune hemolytic anemia accompanied by myelodysplastic syndrome that became Coombs' test negative after azacitidine administration
    Yamada, Shinya
    Kajikawa, Sayaka
    Nakagawa, Noriharu
    Kondo, Yukio
    Okumura, Hirokazu
    ANNALS OF HEMATOLOGY, 2022, 101 (04) : 915 - 917
  • [10] Coombs’ test positive autoimmune hemolytic anemia accompanied by myelodysplastic syndrome that became Coombs’ test negative after azacitidine administration
    Shinya Yamada
    Sayaka Kajikawa
    Noriharu Nakagawa
    Yukio Kondo
    Hirokazu Okumura
    Annals of Hematology, 2022, 101 : 915 - 917
1234